Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204118 | 0.83 | MEN1 (0.61) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL7205283 | 0.78 | KMT2A (0.56) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7166665 | 0.77 | MAPT (0.54) | MAPTMEN1KMT2AMAOBALOX5 | |
| SCHEMBL7191088 | 0.74 | NFE2L2 (0.38) | MAPTMEN1KMT2AMAOBALDH1A1 | |
| SCHEMBL7191091 | 0.74 | NFE2L2 (0.38) | MAPTMEN1KMT2AMAOBALDH1A1 | |
| SCHEMBL13678101 | 0.72 | MAOB (0.78) | MAPTMEN1KMT2AMAOBMAOA | |
| SCHEMBL7205277 | 0.72 | SLC16A3 (0.40) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL6030512 | 0.69 | MEN1 (0.78) | MAPTMEN1KMT2AMAOBALOX5 | |
| SCHEMBL4483006 | 0.69 | MEN1 (0.78) | MAPTMEN1KMT2AMAOBALOX5 | |
| SCHEMBL6028906 | 0.67 | MAOB (0.71) | MAPTMEN1KMT2AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109502-A1 | Novel compounds for modulating cell proliferation | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109502-A1 | Novel compounds for modulating cell proliferation | MKI67, CCNA1, CCNI | MAPT 4740/4885MEN1 1705/4885KMT2A 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.